Tempus AI
Cleanest public "AI + clinical data" name — real pharma contracts. From the Stocktwits tracking list.
$76.05
+7.98%
Short interest
Short % of float
23.2%
Days to cover
3.5d
Shares short
25.38M
Vs Sep 15
-10%
Crowded short. If this turns, covering has to buy a large slice of the float.
Fundamentals-driven short
Revenue, margin, debt, or FCF trend is weak here — this reads more like shorts betting against real business risk than a crowded contrarian squeeze.
Share count and days to cover are the latest FINRA settlement. Short % of float is from Finviz. Prints land about twice a month — fuel for a turn, not today's flow.
No upcoming events in tracker — Finnhub may add earnings when scheduled
SeekingAlpha · 10h ago
SeekingAlpha · 4d ago
Benzinga · 4d ago
Benzinga · 4d ago
Yahoo · 4d ago
Next report
2027-02-22 · Q4 2026 (est.)
EPS est. -0.08 · actual 0.07 (+188.1%)
Last reported · 2026-09-30
Last surprise +188.1% vs estimate
Insider trades (Form 4)
Buys
100,000 sh
$7.6M
Sells
55,512 sh
$4.0M
Net (12 filings)
+44,488 sh
+$3.6M net
Fukushima Ryan (Open-market sale) — 80 sh · $0.0M
Fukushima Ryan (Stock award / grant) — 100,000 sh · $7.6M
Epstein David R (Open-market sale) — 370 sh · $0.0M
LEFKOFSKY ERIC P (Open-market sale) — 13,209 sh · $1.0M
LEFKOFSKY ERIC P (Open-market sale) — 14,237 sh · $1.0M
LEFKOFSKY ERIC P (Open-market sale) — 5,486 sh · $0.4M
LEFKOFSKY ERIC P (Open-market sale) — 1,300 sh · $0.1M
LEFKOFSKY ERIC P (Open-market sale) — 6,636 sh · $0.5M
LEFKOFSKY ERIC P (Open-market sale) — 9,132 sh · $0.6M
LEFKOFSKY ERIC P (Open-market sale) — 2,071 sh · $0.1M
LEFKOFSKY ERIC P (Open-market sale) — 2,167 sh · $0.2M
LEFKOFSKY ERIC P (Open-market sale) — 824 sh · $0.1M
RSI, moving averages, MACD, Bollinger bands & candlestick patterns from Yahoo daily data — verify on chart
Price vs 200-day EMA, plus whether profit shows up as cash. Cash flow, cash, capex growth, and interest coverage sit next to the multiple.
21.7% above 200-day EMA
Growth, margin, debt or FCF trend is weak — a cheap price here may be a value trap, not a discount.
Trailing PE
—
Invest rank
32
Swing rank
50
Earnings skew
dump
Cash flow/share
—
Trailing twelve months
Cash/share
$3.50
Latest quarter
Interest cover
-3.7x
Operating profit / interest
Price / FCF
—
After capex
Rev / share
45.0%
Five-year revenue growth per share
Capex growth
15.2%
5-year rate
Gross margin
64.5%
Prior year 62.7%
Revenue growth
36.6%
YoY, TTM or latest quarter
Net margin
-12.5%
TTM profitability
Debt / equity
269.9%
Lower = less leveraged
FCF growth
—
5Y CAGR, capex-aware
Composite fundamentals score: 25/100 · from Finnhub basic financials, verify against the latest 10-Q before acting.